BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O’Reilly EM. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology. 2009;9:404-409. [PMID: 19451750 DOI: 10.1159/000187135] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Wong YC, Zhang L, Lin G, Zuo Z. Structure–activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. Expert Opinion on Drug Metabolism & Toxicology 2009;5:1399-419. [DOI: 10.1517/17425250903179300] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
2 Sivakumar KC, Haixiao J, Naman CB, Sajeevan TP. Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process. Drug Dev Res 2020;81:685-99. [PMID: 32329098 DOI: 10.1002/ddr.21673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Santo L, Siu KT, Raje N. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Seminars in Oncology 2015;42:788-800. [DOI: 10.1053/j.seminoncol.2015.09.024] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
4 García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
5 Srinivas NR. Recent trends in preclinical drug-drug interaction studies of flavonoids--Review of case studies, issues and perspectives. Phytother Res 2015;29:1679-91. [PMID: 26343418 DOI: 10.1002/ptr.5447] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
6 Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236 [PMID: 24605022 DOI: 10.3748/wjg.v20.i9.2224] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
7 Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Papadimitriou CA, Dimopoulos MA, Filipits M, Bartsch R. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas. 2013;42:760-773. [PMID: 23774698 DOI: 10.1097/mpa.0b013e31827aedef] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
8 Srikumar T, Padmanabhan J. Potential Use of Flavopiridol in Treatment of Chronic Diseases. Adv Exp Med Biol 2016;929:209-28. [PMID: 27771926 DOI: 10.1007/978-3-319-41342-6_9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59:1266-74. [PMID: 22315240 DOI: 10.1002/pbc.24073] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
10 Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015;96:483-497. [PMID: 26481952 DOI: 10.1016/j.critrevonc.2015.07.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
11 Bayraktar S, Rocha Lima CM. Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opinion on Emerging Drugs 2012;17:571-82. [DOI: 10.1517/14728214.2012.739606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ma XH, Shi Z, Tan C, Jiang Y, Go ML, Low BC, Chen YZ. In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening. Pharm Res 2010;27:739-49. [PMID: 20221898 DOI: 10.1007/s11095-010-0065-2] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
13 Onesti CE, Romiti A, Roberto M, Falcone R, Marchetti P. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Rev Anticancer Ther 2015;15:1183-98. [PMID: 26325474 DOI: 10.1586/14737140.2015.1081816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-18. [DOI: 10.1007/s00432-011-1039-4] [Cited by in Crossref: 158] [Cited by in F6Publishing: 142] [Article Influence: 14.4] [Reference Citation Analysis]
15 Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A, Valius M. Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers (Basel). 2014;6:2224-2242. [PMID: 25349887 DOI: 10.3390/cancers6042224] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 9.6] [Reference Citation Analysis]
16 Cotterell J. Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient. Onco Targets Ther 2014;7:655-62. [PMID: 24833909 DOI: 10.2147/OTT.S45232] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs 2012;30:629-38. [PMID: 20938713 DOI: 10.1007/s10637-010-9563-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
18 Song Y, Xin X, Zhai X, Xia Z, Shen K. Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res 2014;7:121. [PMID: 25528169 DOI: 10.1186/s13048-014-0121-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
19 Wang K, Hampson P, Hazeldine J, Krystof V, Strnad M, Pechan P, M J. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis. PLoS One 2012;7:e30128. [PMID: 22276149 DOI: 10.1371/journal.pone.0030128] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
20 Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters GJ, Giovannetti E, Diana P. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers (Basel) 2021;13:4389. [PMID: 34503199 DOI: 10.3390/cancers13174389] [Reference Citation Analysis]
21 Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs. 2015;24:781-794. [PMID: 25809274 DOI: 10.1517/13543784.2015.1026963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Yee NS. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Adv Exp Med Biol 2013;779:91-143. [PMID: 23288637 DOI: 10.1007/978-1-4614-6176-0_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
24 Bisol Â, de Campos PS, Lamers ML. Flavonoids as anticancer therapies: A systematic review of clinical trials. Phytother Res 2020;34:568-82. [PMID: 31752046 DOI: 10.1002/ptr.6551] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
25 Shafiq MI, Steinbrecher T, Schmid R. Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling. PLoS One 2012;7:e42612. [PMID: 22905154 DOI: 10.1371/journal.pone.0042612] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
26 Erol A, Acikgoz E, Guven U, Duzagac F, Turkkani A, Colcimen N, Oktem G. Ribosome biogenesis mediates antitumor activity of flavopiridol in CD44+/CD24- breast cancer stem cells. Oncol Lett 2017;14:6433-40. [PMID: 29422957 DOI: 10.3892/ol.2017.7029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
27 Mikhail S, Albanese C, Pishvaian MJ. Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers. Am J Pathol 2015;185:1185-97. [PMID: 25747534 DOI: 10.1016/j.ajpath.2015.01.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]